Alnylam Pharmaceuticals (ALNY) revenue

Revenue · fiscal 2025
$3.71B

Alnylam Pharmaceuticals (ALNY) reported revenue of $3.71B in fiscal 2025 (the year ended December 31, 2025). That is 65.2% higher than the $2.25B of fiscal 2024. Figures as of 19 Nov 2026, 11:18 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$3.71B
Change on fiscal 2024
+65.2%
Growth, 5 years
+49.8% a year
Highest on record
$3.71Bfiscal 2025
Lowest on record
$47.16Mfiscal 2016
Fiscal years on record
132008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Alnylam Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 49.8% a year. Across the 13 fiscal years on record (2008–2025), the highest was $3.71B in fiscal 2025 and the lowest $47.16M in fiscal 2016.

History · 13 fiscal years

Revenue by fiscal year

Alnylam Pharmaceuticals revenue, year by year

Alnylam Pharmaceuticals (ALNY) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$3.71B 65.2% up
2024$2.25B 23.0% up
2023$1.83B 76.2% up
2022$1.04B 22.9% up
2021$844.29M 71.3% up
2020$492.85M 124.3% up
2019$219.75M 193.4% up
2018$74.91M 16.7% down
2017$89.91M 90.7% up
2016$47.16M—
2010$100.04M 0.5% down
2009$100.53M 4.5% up
2008$96.16M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Alnylam Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
BioNTech BNTX€2.87B2025
Alnylam Pharmaceuticals ALNY$3.71B2025
Medpace Holdings MEDP$2.53B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ALNY

Alnylam Pharmaceuticals, figure by figure

Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value

Alnylam Pharmaceuticals revenue: questions and answers

What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals (ALNY) reported revenue of $3.71B in fiscal 2025 (the year ended December 31, 2025). That is 65.2% higher than the $2.25B of fiscal 2024.

What is the growth rate of Alnylam Pharmaceuticals's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 49.8% a year.

What are the highest and lowest revenue figures on record for Alnylam Pharmaceuticals?

Across the 13 fiscal years on record (2008–2025), the highest was $3.71B in fiscal 2025 and the lowest $47.16M in fiscal 2016.

How is Alnylam Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Alnylam Pharmaceuticals it is on record here for 13 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals (ALNY) revenue”, data as of 19 November 2026. https://funkfolio.com/stock/ALNY/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.